Published in Ther Clin Risk Manag on March 31, 2017
Defining comorbidity: implications for understanding health and health services. Ann Fam Med (2009) 5.78
The impact of comorbid chronic conditions on diabetes care. Diabetes Care (2006) 5.42
NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA (1993) 4.91
Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol (2010) 3.55
The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int (1999) 3.19
A systematic review of the association between erectile dysfunction and cardiovascular disease. Eur Urol (2013) 3.12
Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol (2006) 2.57
The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol (2004) 2.34
Definitions/epidemiology/risk factors for sexual dysfunction. J Sex Med (2010) 2.17
The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin (2004) 2.03
High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. Int J Impot Res (2002) 1.63
Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. Int J Clin Pract (2013) 1.61
Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. J Sex Med (2012) 1.47
Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet (1985) 1.45
Erectile function, erection hardness and tolerability in men treated with sildenafil 100 mg vs. 50 mg for erectile dysfunction. Int J Clin Pract (2013) 1.42
Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol (2005) 1.36
Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy. Drugs Aging (2010) 1.23
Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation (2004) 1.19
PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res (2007) 1.14
Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol (2005) 1.09
Geriatric drug therapy: neglecting the inevitable majority. Ageing Res Rev (2010) 1.02
Drug related problems in type 2 diabetes patients with hypertension: a cross-sectional retrospective study. BMC Endocr Disord (2013) 1.00
Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol (2001) 0.93
Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. Circulation (2010) 0.93
Erectile dysfunction and hypertension. Int J Impot Res (2006) 0.92
Treatment Strategy for Non-Responders to PDE5 Inhibitors. World J Mens Health (2013) 0.92
Erectile dysfunction in the elderly: an old widespread issue with novel treatment perspectives. Int J Endocrinol (2014) 0.89
Treatment of infertility in men with spinal cord injury. Nat Rev Urol (2010) 0.89
New insights into hypertension-associated erectile dysfunction. Curr Opin Nephrol Hypertens (2012) 0.89
Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. Int J Hypertens (2012) 0.87
Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: a systematic literature review. BMC Nephrol (2011) 0.87
Vardenafil treatment for erectile dysfunction. Ann Pharmacother (2004) 0.86
Global perspectives and controversies in the epidemiology of male erectile dysfunction. Curr Opin Urol (2002) 0.86
Erectile dysfunction and cardiac disease: recommendations of the Second Princeton Conference. Curr Urol Rep (2006) 0.86
Drug-related problems in type 2 diabetes mellitus patients with dyslipidemia. BMC Public Health (2013) 0.86
Evaluation of erectile dysfunction therapy in patients previously nonadherent to long-term medications: a retrospective analysis of prescription claims. Am J Ther (2005) 0.85
Hardness, function, emotional well-being, satisfaction and the overall sexual experience in men using 100-mg fixed-dose or flexible-dose sildenafil citrate. Int J Impot Res (2010) 0.84
Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian J Pharm Sci (2012) 0.84
Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors? Sex Med (2014) 0.82
Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients. Int J Impot Res (2013) 0.82
End-stage renal disease and erectile dysfunction. Is there any hope? Nephrol Dial Transplant (2000) 0.82
Assessing satisfaction in men and their female partners after treatment with phosphodiesterase type 5 inhibitors for erectile dysfunction. Int J Impot Res (2013) 0.80
Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res (2005) 0.80
Oral drug treatments in patients with erectile dysfunction and multiple comorbidities: a retrospective observational study. BMJ Open (2014) 0.80
Management of erectile dysfunction in hypertension: Tips and tricks. World J Cardiol (2014) 0.80
Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. Cent European J Urol (2014) 0.79
Polypharmacy in the elderly. J Res Pharm Pract (2015) 0.79
Polypharmacy. Keeping the elderly safe. RN (2005) 0.77
Benign prostatic hyperplasia and erectile dysfunction--is there a link? Curr Med Res Opin (2000) 0.77
Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation. J Sex Med (2013) 0.77
Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates. Curr Med Res Opin (2010) 0.77
Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction. Andrologia (2014) 0.76
Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension. Intern Med J (2001) 0.76
Ethnicity is an independent determinant of age-specific PSA level: findings from a multiethnic Asian setting. PLoS One (2014) 0.80
Association of psychological factors, patients' knowledge, and management among patients with erectile dysfunction. Patient Prefer Adherence (2016) 0.75
A Study on the Immunohistochemical Expressions of Leptin and Leptin Receptor in Clear Cell Renal Cell Carcinoma. Biomed Res Int (2020) 0.75